Abstract Number: 1695 • ACR Convergence 2023
Single Cell Transcriptomics in Kidney Tissue from African American Patients Enrolled in the Accelerating Medicines Partnership (AMP) Implicates Tubular Cells in the Pathogenesis of APOL1 Associated Lupus Nephritis
Background/Purpose: The G1 and G2 risk variants (RVs) in Apolipoprotein L1 (APOL1) associate with CKD and may contribute to poorer outcomes for African American (AA)…Abstract Number: 0112 • ACR Convergence 2023
Molecular Stratification of Antiphospholipid Syndrome Patients Through Integrative Analysis of the Whole-blood RNA Transcriptome
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease associated with diverse clinical manifestations in the setting of persistent antiphospholipid antibodies (aPL). Early diagnosis and…Abstract Number: 1709 • ACR Convergence 2023
Tape Stripping Expression Signatures Identify Biologically Unique Juvenile Dermatomyositis Patient Subgroup Characterized by Increased Mitochondrial Dysfunction
Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) can signal disease onset or flare and prevent complete disease remission. The study of cutaneous expression signatures holds…Abstract Number: 0114 • ACR Convergence 2023
Platelets Are Highly Activated and Could Participate in Immune Abnormality of APS
Background/Purpose: Platelets play a pivotal role in the process of coagulation and other biological process. Studies have shown multiple evidences that platelets are highly activated…Abstract Number: 1738 • ACR Convergence 2023
Identification of Homeostatic and Inflammatory Synovial Fibroblast Signatures in Synovial Tissue Biopsies of Healthy Controls and Patients with Rheumatoid Arthritis
Background/Purpose: Recent literature has identified different synovial fibroblast (FLS) populations within RA synovium with distinct inflammatory profiles. Despite current advances in classifying heterogeneity of FLS…Abstract Number: 0265 • ACR Convergence 2023
Differential and Combinatorial Mechanism of Action of Golimumab and Guselkumab in Ulcerative Colitis Induction Therapy: IL-23 Blockade Drives Restoration of Normal Epithelium and Mucosal Healing
Background/Purpose: The combination treatment of golimumab (GOL), a tumor necrosis factor-alpha (TNFα) antagonist, and guselkumab (GUS), an interleukin (IL)-23 inhibitor was shown to induce higher…Abstract Number: 1762 • ACR Convergence 2023
Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls
Background/Purpose: Single-cell analysis has emerged as a powerful tool for investigating the transcriptomics and T-cell receptor (TCR) diversity in patients with rheumatoid arthritis (RA). However,…Abstract Number: 0594 • ACR Convergence 2023
Baseline Innate Immunity Transcriptional Signatures Act as Predictors of Response to Immunosuppressive and Biologic Treatments in Systemic Lupus Erythematosus While Disturbances Linked to p53-signaling Define “Resistant” Disease
Background/Purpose: Despite recent advances, the current state of SLE therapeutics remains largely empirical with existing immunosuppressive treatments failing to induce remission in over 40% of…Abstract Number: 1770 • ACR Convergence 2023
Dual Inhibition of TNF-α and OX40L on Synovial Inflammation and Osteoclastogenesis in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease that leads to progressive cartilage and bone destruction. TNF superfamily member OX40 ligand (OX40L; CD252) is…Abstract Number: 0598 • ACR Convergence 2023
Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study
Background/Purpose: Litifilimab is a humanized IgG1 mAb targeting BDCA2, a receptor expressed on plasmacytoid dendritic cells (pDCs), that negatively regulates the production of Type I…Abstract Number: 1791 • ACR Convergence 2023
Exploring the Mechanism of Anti-TNFα Therapy Non-response in Psoriatic Arthritis: The Role of TNF Receptor 2 Polymorphisms rs1061622
Background/Purpose: Despite the widespread use of anti-TNFα therapy in psoriatic arthritis (PsA), a significant proportion of patients fail to achieve a complete treatment response. There…Abstract Number: 0733 • ACR Convergence 2023
Global Identification of Lupus Genetic Risk Variants Facilitating the Type I Interferon Pathway Through CRISPR-based Genomic Screening
Background/Purpose: Genome-Wide Association Studies (GWAS) have unveiled over 1000 risk variants for lupus, predominantly situated in non-coding genomic regions. Their functional roles, especially their potential…Abstract Number: 2171 • ACR Convergence 2023
Common IL-6 Signaling Is Inhibited by IL-6 Inhibitors and JAK Inhibitors, but Which Is Better at Preventing Bone Destruction in RA?
Background/Purpose: To date, there are no head-to-head clinical trials directly comparing the effects between IL-6i and JAKi on bone destruction in RA. In recent years,…Abstract Number: 0830 • ACR Convergence 2023
The Upregulation of MAP Kinase Pathway Genes Is Associated with Poor Treatment Response to Tofacitinib in Polyarticular Course Juvenile Idiopathic Arthritis
Background/Purpose: Despite significant progress in understanding the pathophysiology of Juvenile Idiopathic Arthritis (JIA), the availability of tools to accurately predict treatment response remains limited. Our…Abstract Number: 2180 • ACR Convergence 2023
Salivary and Plasma Mitochondrial Double-strand RNAs as a Diagnostic Biomarker for Sjӧgren Syndrome
Background/Purpose: Since mitochondrial double-stranded RNAs (mt-dsRNAs), an endogenous activator of interferon signaling, are elevated in primary Sjӧgren's syndrome (pSS), we evaluated their association with the…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 31
- Next Page »